Novo Nordisk signs $3.3bn deal to acquire Dicerna Pharmaceuticals

Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) ... Read More